Vergent Bioscience, a Minneapolis-based cancer-focused biotechnology company, raised $8.7m in Series A financing.
The round was led by Spring Mountain Capital.
The company intends to use the funds to advance its preclinical and clinical development activities.
Led by John Santini, President and CEO, Vergent is developing a tumor-targeted, fluorescent probe to help surgeons quickly identify and completely remove cancerous tissue during surgery. Its molecularly-targeted probe binds to enzymes overexpressed in tumor tissue, activating a brightly fluorescing dye. The cancer “lights up,” providing the surgeon a clear visual guide for the removal of the tumor and associated metastases.
Vergent’s proprietary probe is under development for use in multiple cancers including lung, breast, ovarian, colorectal, and brain, among others.